Phibro Animal Health
Phibro Animal Health is a U.S.-incorporated animal health and mineral nutrition company serving livestock producers and related agricultural markets.
Last updated August 25, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
Phibro Animal Health Corporation is an American company focused on animal health, livestock nutrition, and related performance materials. Its business is organized around three principal segments: Mineral Nutrition, Performance Materials, and Animal Health. The Animal Health segment includes products used in livestock production, including antibacterials, anticoccidials, anthelmintics, vaccines, and other health-management products. The company’s mineral nutrition activities address the dietary and production requirements of animals, while the Performance Materials segment broadens the company’s activities beyond its core animal-health portfolio. The business was established in 1946 under the name Philipp Brothers Chemicals, Inc. Its later development was shaped by acquisitions and portfolio expansion. In 1974, it acquired Koffolk, an Israeli animal nutrition company, adding a more direct presence in livestock nutrition. In 2000, Pfizer sold its medicated feed-additives business to Phibro Animal Health, a transaction that strengthened Phibro’s position in animal-health products used in feed and livestock production. The company adopted the Phibro Animal Health name in 2003, reflecting the increasing importance of animal health within its identity and commercial activities. Further expansion followed in 2009, when the company acquired Baltzell’s U.S. mineral nutrition business and ABIC Laboratories, an Israeli vaccine maker. These transactions reinforced both the Mineral Nutrition and Animal Health segments and gave the company additional capabilities in vaccines. In 2014, Phibro Animal Health completed an initial public offering and became listed on the Nasdaq, marking a transition to public-company ownership and reporting. In 2018, it established a biotechnology facility in Sligo, Ireland, dedicated to producing animal-health vaccines. The facility was described as the company’s first manufacturing plant in Europe. Phibro operates across a geographically diverse network covering North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific region. Its offerings are directed primarily at livestock and commercial animal production rather than consumer pet care. The company’s business model combines pharmaceutical and biological products with nutritional inputs and performance-related materials, allowing it to participate in several parts of the livestock-production value chain. Its products are used in settings where disease prevention, treatment, feed efficiency, mineral supplementation, and animal productivity are important operational concerns. The company’s positioning is therefore broader than that of a single-category veterinary pharmaceutical manufacturer. It combines animal-health products with nutrition and materials businesses, while maintaining an international manufacturing and commercial footprint. Publicly available reference material identifies Phibro Animal Health as a Delaware-incorporated American corporation and documents its Nasdaq listing following the 2014 offering, but does not provide sufficient information here to establish its current ticker, headquarters address, current executive roster, financial metrics, or official website URL.
History
Phibro Animal Health traces its origins to 1946, when it was founded as Philipp Brothers Chemicals, Inc. The company did not begin with the present-day name; instead, its corporate identity evolved as animal health and livestock nutrition became increasingly central to its activities. A significant early expansion occurred in 1974 through the acquisition of Koffolk, an animal nutrition company based in Israel. This transaction broadened the company’s involvement in animal nutrition and established an early international dimension to its business. In 2000, Pfizer sold its medicated feed-additives business to Phibro Animal Health. The acquisition expanded Phibro’s presence in animal-health products delivered through livestock feed and strengthened its participation in the commercial animal-production market. Three years later, in 2003, the company changed its name from Philipp Brothers Chemicals to Phibro Animal Health. The renaming reflected the company’s strategic identity as an animal-health and nutrition business rather than a general chemicals company. The company continued to develop through acquisitions in 2009. It purchased Baltzell’s U.S. mineral nutrition business, adding capabilities in a field that became one of its principal operating segments. In the same year, it acquired ABIC Laboratories, an Israeli vaccine maker. The ABIC transaction expanded Phibro’s biological-products portfolio and supported its involvement in vaccines for animal health. Together, the 2009 acquisitions reinforced the company’s two-sided structure: animal-health products on one side and mineral nutrition on the other. A major corporate milestone came in 2014, when Phibro Animal Health held an initial public offering and became listed on the Nasdaq. The offering transformed the company into a publicly traded business and created a new framework for capital access, governance, and public reporting. The available reference material does not specify the company’s ticker symbol or provide financial details for the offering. In 2018, Phibro established a biotechnology facility in Sligo, Ireland, for the production of animal-health vaccines. The facility was identified as the company’s first manufacturing plant in Europe, extending its production footprint beyond its existing operations in other regions. The Sligo investment also underscored the importance of biological products within Phibro’s animal-health activities. Phibro’s documented business structure consists of Mineral Nutrition, Performance Materials, and Animal Health. The Animal Health segment includes antibacterials, anticoccidials, anthelmintics, and vaccines for livestock. The company’s geographic reach includes the United States, Latin America, Canada, Europe, the Middle East, Africa, and the Asia-Pacific region. This combination of product categories and geographic markets distinguishes Phibro from a narrowly focused veterinary-drug company: it operates across animal disease management, livestock nutrition, and related performance materials. The supplied reference material does not identify a founder, current chief executive, headquarters location, current owner, parent company, current ticker, or subsequent corporate events after the 2018 Sligo facility announcement. Those fields are therefore left unreported rather than inferred.
- 2018
European vaccine manufacturing facility established
[1]The company established a biotechnology facility in Sligo, Ireland, producing animal-health vaccines and becoming Phibro’s first manufacturing plant in Europe.
- 2014
Initial public offering and Nasdaq listing
[1]Phibro Animal Health completed an initial public offering and became a Nasdaq-listed company.
- 2009
Mineral nutrition and vaccine acquisitions
[1]Phibro acquired Baltzell’s U.S. mineral nutrition business and ABIC Laboratories, an Israeli vaccine maker.
- 2003
Corporate name changed to Phibro Animal Health
[1]The company changed its name from Philipp Brothers Chemicals to Phibro Animal Health, aligning its corporate identity with its animal-health focus.
- 2000
Pfizer medicated feed-additives business acquired
[1]Phibro purchased Pfizer’s medicated feed-additives business, strengthening its animal-health and livestock-feed portfolio.
- 1974
Acquisition of Koffolk
[1]Phibro acquired Koffolk, an animal nutrition company based in Israel, expanding its presence in livestock nutrition and international operations.
- 1946
Company founded as Philipp Brothers Chemicals
[1]The business was established as Philipp Brothers Chemicals, Inc., providing the corporate foundation from which Phibro Animal Health later developed.
Products and positioning
An international livestock-health and nutrition company combining veterinary pharmaceuticals, vaccines, mineral nutrition, and performance materials for commercial animal production.
Animal health
Antibacterials
Phibro’s antibacterial products are part of its livestock animal-health portfolio. They are intended for use in animal-production settings where bacterial disease management is required. The supplied reference material identifies antibacterials as one of the company’s principal product categories but does not specify individual product names, formulations, indications, or markets.
Animal health
Anticoccidials
Anticoccidials form part of Phibro’s livestock-health offering and are associated with the management of coccidial disease in animal-production systems. The category is listed among the company’s animal-health products, although the available material does not provide product-level details or identify specific livestock species.
Animal health
Anthelmintics
Phibro includes anthelmintics among its animal-health products for livestock. These products belong to the parasite-control portion of the portfolio. No individual brands, launch dates, active ingredients, regulatory approvals, or geographic restrictions are identified in the supplied reference material.
Veterinary biologics
Animal-health vaccines
Vaccines are a significant component of Phibro’s animal-health activities. The company acquired ABIC Laboratories in 2009 and later established a biotechnology manufacturing facility in Sligo, Ireland, in 2018. The available source describes the facility as producing animal-health vaccines but does not identify specific vaccine brands or diseases covered.
Animal nutrition
Mineral nutrition
Mineral Nutrition is one of Phibro Animal Health’s three principal business segments. Its products support the mineral requirements of livestock and fit within the company’s broader emphasis on animal productivity and production management. The segment was reinforced by the 2009 acquisition of Baltzell’s U.S. mineral nutrition business.
Livestock production inputs
Medicated feed additives
Medicated feed additives became an important part of Phibro’s animal-health portfolio after the company acquired Pfizer’s related business in 2000. These products are delivered through livestock feed systems, connecting animal disease management with commercial production practices. Specific products and current regulatory status are not provided in the source material.
Performance materials
Performance Materials
Performance Materials is one of the company’s three reported operating segments. It represents activities outside the narrower animal-health and mineral-nutrition categories. The supplied reference identifies the segment but does not describe its individual products, end markets, or manufacturing technologies.
Brand decisions
2018
Establishment of Sligo biotechnology facilityStrategyBackground
Phibro expanded its vaccine-production infrastructure and sought a European manufacturing base for animal-health biologicals.
Action taken
The company established a biotechnology facility in Sligo, Ireland, for producing animal-health vaccines.
Aftermath
The facility became Phibro’s first manufacturing plant in Europe and increased its direct vaccine-production capacity.
2014
Initial public offeringOtherBackground
Phibro moved from private ownership to public-market participation as part of its corporate development.
Action taken
The company held an initial public offering and became listed on the Nasdaq.
Aftermath
The offering established Phibro as a publicly traded company, although the supplied material does not provide the ticker or offering financials.
2009
Expansion through mineral nutrition and vaccine acquisitionsM&ABackground
Phibro sought to strengthen two complementary parts of its portfolio: mineral nutrition and animal-health biologics.
Action taken
The company acquired Baltzell’s U.S. mineral nutrition business and ABIC Laboratories in Israel.
Aftermath
The acquisitions expanded Phibro’s mineral-nutrition operations and added an Israeli vaccine business to its animal-health activities.
2003
Rebranding as Phibro Animal HealthStrategyBackground
The former Philipp Brothers Chemicals identity no longer fully represented the company’s increasing concentration on animal health and nutrition.
Action taken
The company changed its corporate name to Phibro Animal Health.
Aftermath
The new name made animal health the central element of the company’s public identity.
2000
Acquisition of Pfizer’s medicated feed-additives businessM&ABackground
Phibro pursued the acquisition as part of its expansion in animal-health products and livestock feed additives.
Action taken
The company acquired Pfizer’s medicated feed-additives business.
Aftermath
The transaction broadened Phibro’s presence in medicated livestock-feed products and strengthened its animal-health portfolio.
Sources1 sources
Cite this profile: Cite the canonical profile. /brand-wiki/phibro-animal-health · Editorial policy · How profiles are compiled